| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $4.3M | -25.9% | -50.2% |
| SG&A Expense | $4.3M | -3.8% | -40.0% |
| Operating Income | -$8.7M | +16.2% | +58.2% |
| Net Income | -$7.7M | +17.4% | +59.9% |
| EPS (Basic) | -$2.44 | +17.6% | -687.1% |
| EPS (Diluted) | -$2.44 | +17.6% | -687.1% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $52.8M | -8.4% | +63.4% |
| Current Assets | $55.7M | -7.6% | -36.1% |
| Total Assets | $74.2M | -6.4% | -33.6% |
| Current Liabilities | $22.2M | +12.3% | +31.2% |
| Total Liabilities | $43.0M | +5.1% | +10.3% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$25.0M | — | — |
| Investing Cash Flow | $40.2M | — | — |
| Financing Cash Flow | $14K | — | — |
| $31.1M |
| -18.7% |
| -57.2% |